JAK Inhibitor Therapy
نویسندگان
چکیده
منابع مشابه
Methotrexate Is a JAK/STAT Pathway Inhibitor
BACKGROUND The JAK/STAT pathway transduces signals from multiple cytokines and controls haematopoiesis, immunity and inflammation. In addition, pathological activation is seen in multiple malignancies including the myeloproliferative neoplasms (MPNs). Given this, drug development efforts have targeted the pathway with JAK inhibitors such as ruxolitinib. Although effective, high costs and side e...
متن کاملSuppress for Success: A JAK Inhibitor for Adjunct Therapy of Tuberculosis
Standard chemotherapy of tuberculosis (TB), which is caused by infection withMycobacterium tuberculosis (Mtb) and which primarily affects the lung, consists of a combination of antimicrobial drugs (isoniazid, rifampin, ethambutol and pyrazinamide). Concomitant administration of these antimicrobials helps eradicate active infection and prevents disease relapse (Zumla et al., 2015). In most patie...
متن کاملThe effects of JAK inhibitor therapy upon novel markers of thrombosis In myeloproliferative neoplasms.
Thrombosis is a relatively common and potentially life-threatening complication of myeloproliferative neoplasms (MPN). The introduction of JAK inhibitors (JAKi) has had a profound effect upon the therapeutic landscape for MPN, however, potential effects of these drugs upon thrombotic risk is largely unknown. Our objective was to study, in a MPN patient cohort, the in vivo effects of these agent...
متن کاملJak Inhibitor Clinical Response in Polyarthritis: Case Report.
The heterogeneity of rheumatoid arthritis (RA) presentation and molecular signature of RA subclasses in patients with early changes of small peripheral joints still remains a challenging problem. In clinical setting, classification of the disease subtypes is not possible and treatment adjustment is based on the continuous Disease Activity Score for disease severity recognition. A new approach i...
متن کاملJAK inhibitor: tofacitinib, a new disease modifying anti-rheumatic drug
Treatment of rheumatoid arthritis (RA) with biologic agents targeting inflammatory cytokines and cell surface molecules such as tumor necrosis factor and Interleukin-6 is generally more efficacious than traditional disease-modifying antirheumatic drugs when combined with MTX. However, not only do ~30% of patients poorly respond to treatment but also parenteral mode of administration and expense...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncology Times
سال: 2019
ISSN: 0276-2234
DOI: 10.1097/01.cot.0000577152.54847.a8